Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: drug discovery - AbbVie/ExonHit

Next Previous
X
Search
Drug Profile

Research programme: drug discovery - AbbVie/ExonHit

Alternative Names: AGN 002; EHT 002; EHT/AGN 0002; EHT/AGN 0003; EHT/AGN 002

Latest Information Update: 18 May 2020

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allergan; ExonHit Therapeutics
  • Developer AbbVie; Eurobio Scientific
  • Class Antibodies; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Eye disorders; Neurodegenerative disorders; Pain

Most Recent Events

  • 08 May 2020 Allergan has been acquired and merged into AbbVie
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Eye-disorders in France (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in France (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top